Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-31No description of principal activitytrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.falsefalse12024-01-011false SC726725 2024-01-01 2024-12-31 SC726725 2023-01-01 2023-12-31 SC726725 2024-12-31 SC726725 2023-12-31 SC726725 c:Director1 2024-01-01 2024-12-31 SC726725 c:RegisteredOffice 2024-01-01 2024-12-31 SC726725 d:CurrentFinancialInstruments 2024-12-31 SC726725 d:CurrentFinancialInstruments 2023-12-31 SC726725 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 SC726725 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 SC726725 d:ShareCapital 2024-12-31 SC726725 d:ShareCapital 2023-12-31 SC726725 d:RetainedEarningsAccumulatedLosses 2024-12-31 SC726725 d:RetainedEarningsAccumulatedLosses 2023-12-31 SC726725 c:OrdinaryShareClass1 2024-01-01 2024-12-31 SC726725 c:OrdinaryShareClass1 2024-12-31 SC726725 c:OrdinaryShareClass1 2023-12-31 SC726725 c:FRS102 2024-01-01 2024-12-31 SC726725 c:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 SC726725 c:FullAccounts 2024-01-01 2024-12-31 SC726725 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 SC726725 e:PoundSterling 2024-01-01 2024-12-31 xbrli:shares iso4217:GBP xbrli:pure
Registered number: SC726725










BEACTICA THERAPEUTICS UK LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

 
BEACTICA THERAPEUTICS UK LIMITED
 

COMPANY INFORMATION


Director
Dr P Kallblad 




Registered number
SC726725



Registered office
C/o EQ Accountants Limited
Pentland House

Saltire Centre

Glenrothes

Fife

KY6 2AH




Accountants
EQ Accountants Limited
Chartered Accountants

Pentland House

Saltire Centre

Glenrothes

Fife

KY6 2AH





 
BEACTICA THERAPEUTICS UK LIMITED
REGISTERED NUMBER: SC726725

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2024

2024
2023
£
£

  

Current assets
  

Debtors Within One Year
 4 
26,300
-

Bank and cash balances
  
12,680
6,620

  
38,980
6,620

Creditors: amounts falling due within one year
 5 
(32,064)
(4,464)

Net current assets
  
 
 
6,916
 
 
2,156

Total assets less current liabilities
  
6,916
2,156

  

Net assets
  
6,916
2,156


Capital and reserves
  

Called up share capital 
 6 
100
100

Profit and loss account
  
6,816
2,056

  
6,916
2,156


Page 1

 
BEACTICA THERAPEUTICS UK LIMITED
REGISTERED NUMBER: SC726725

STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2024

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Dr P Kallblad
Director

Date: 15 September 2025

The notes on pages 3 to 5 form part of these financial statements.

Page 2

 
BEACTICA THERAPEUTICS UK LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1.


General information

Beactica Therapeutics UK Limited is a private company, limited by shares, incorporated in Scotland with registration number SC726725. The registered office is C/o EQ Accountants Limited, Pentland House, Saltire Centre, Glenrothes, KY6 2AH.
The financial statements are presented in Sterling which is the functional currency of the company and rounded to the nearest £.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

At the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Page 3

 
BEACTICA THERAPEUTICS UK LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.4

Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the Company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before turnover is recognised:

Rendering of services

Turnover from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of turnover can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.5

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.


 
2.6

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Statement of financial position when the Company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.


3.


Employees

The average monthly number of employees, including directors, during the year was 1 (2023 - 1).

Page 4

 
BEACTICA THERAPEUTICS UK LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

4.


Debtors

2024
2023
£
£


Trade debtors
26,108
-

Prepayments and accrued income
192
-

26,300
-



5.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
610
1,332

Other taxation and social security
1,766
482

Other creditors
805
-

Accruals and deferred income
28,883
2,650

32,064
4,464



6.


Share capital

2024
2023
£
£
Allotted, called up and fully paid



100 (2023 - 100) Ordinary shares of £1.00 each
100
100



7.


Controlling party

The company's ultimate parent and controlling party is Beactica Therapeutics AB, a company incorporated in Sweden.


Page 5